Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| A5951054 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| linezolid | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Resolution of infection at the time of completion of therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Kamogawa | Chiba | 296-0041 | Japan | ||
| Pfizer Investigational Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fukuoka |
| Fukuoka |
| 811-0213 |
| Japan |
| Pfizer Investigational Site | Fukuoka | Fukuoka | 813-0025 | Japan |
| Pfizer Investigational Site | Onga-gun | Fukuoka | 807-0051 | Japan |
| Pfizer Investigational Site | Hiroshima | Hiroshima | 730-8619 | Japan |
| Pfizer Investigational Site | Hiroshima | Hiroshima | 734-8530 | Japan |
| Pfizer Investigational Site | Sappopro | Hokkaido | 060-8648 | Japan |
| Pfizer Investigational Site | Sapporo | Hokkaido | 006-8555 | Japan |
| Pfizer Investigational Site | Moriya | Ibaraki | 302-0118 | Japan |
| Pfizer Investigational Site | Yokohama | Kanagawa | 236-0051 | Japan |
| Pfizer Investigational Site | Kyoto | Kyoto | 615-8256 | Japan |
| Pfizer Investigational Site | Isahaya | Nagasaki | 854-8501 | Japan |
| Pfizer Investigational Site | Nagasaki | Nagasaki | 852-8501 | Japan |
| Pfizer Investigational Site | Kurashiki | Okayama-ken | 701-0912 | Japan |
| Pfizer Investigational Site | Kurashiki | Okayama-ken | Japan |
| Pfizer Investigational Site | Okayama | Okayama-ken | 700-8505 | Japan |
| Pfizer Investigational Site | Okayama | Okayama-ken | 703-8275 | Japan |
| Pfizer Investigational Site | Suita | Osaka | 565-8565 | Japan |
| Pfizer Investigational Site | Iruma-gun | Saitama | 350-0495 | Japan |
| Pfizer Investigational Site | Kodaira | Tokyo | 187-0004 | Japan |
| ID | Term |
|---|---|
| D003428 | Cross Infection |
| ID | Term |
|---|---|
| D007239 | Infections |
| D007049 | Iatrogenic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069349 | Linezolid |
| ID | Term |
|---|---|
| D000081 | Acetamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000085 | Acetates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D023303 | Oxazolidinones |
| D010080 | Oxazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided